Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06641206

Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain

Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chronic Knee Pain

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, El Gharbyia, 13511, Egypt

Location status: Recruiting

Location contact

Ali El Deeb, Professor

CONTACT

[email protected]

01222800335 ext. +2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients were not assigned for surgical intervention;
  • Patients were free of exclusion criteria

Exclusion criteria

  • Patients were assigned for surgical intervention;
  • Patients who had uncontrolled hypertension and/or diabetes mellitus;
  • Patients who had uncompensated cardiac, renal, or hepatic diseases;
  • Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;
  • Patients who refused to sign the informed consent were excluded from the study.

Treatment and study plan

Triamcinolone Acetonide

Drug

1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain

Bupivacaine Hydrochloride

Drug

20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain

Dexmedetomidine

Drug

Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline

Primary outcomes

  1. Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection.

    Time frame: 7 months

    Value of intra-articular Injection in Pain Reduction of chronic knee pain manifested by recurrence of pain.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Intra-articular Dexmedetomidine for Treatment of Chronic Knee Pain: A Prospective Case-Control Clinical Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 15, 2024
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.